Moderna (MRNA) Tops Q2 EPS by 85c; offers guidance

Moderna (NASDAQ: MRNA) reported Q2 EPS of ($2.13), $0.85 better than the analyst estimate of ($2.98). Revenue for the quarter came in at $142 million versus the consensus estimate of $114.4 million.

GUIDANCE:

Moderna sees FY2025 revenue of $1.5-2.2 billion, versus the consensus of $2.068 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy
• Worthington Industries (WOR) Misses Q4 EPS by 9c